77 related articles for article (PubMed ID: 22428523)
1. Valsartan, an angiotensin receptor blocker treats sexual dysfunction in a female hypertensive: a case report.
Okeahialam BN
Afr J Med Med Sci; 2011 Sep; 40(3):273-5. PubMed ID: 22428523
[TBL] [Abstract][Full Text] [Related]
2. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
Baser O; Andrews LM; Wang L; Xie L
J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
[TBL] [Abstract][Full Text] [Related]
3. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Phipps JA; Wilkinson-Berka JL; Fletcher EL
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):927-34. PubMed ID: 17251496
[TBL] [Abstract][Full Text] [Related]
4. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
Weisser B; Vetter H; Mengden T
Dtsch Med Wochenschr; 2003 Mar; 128(11):541-4. PubMed ID: 12635025
[TBL] [Abstract][Full Text] [Related]
5. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
6. [Successful treatment of combination therapy using an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker in a patient with IgA nephropathy].
Horino T; Ito H; Tanimoto N; Yoshida T; Sasaoka A; Chijiwa T; Hosokawa T; Hashimoto K
Nihon Jinzo Gakkai Shi; 2003; 45(2):104-8. PubMed ID: 12703406
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
9. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men.
Fogari R; Preti P; Derosa G; Marasi G; Zoppi A; Rinaldi A; Mugellini A
Eur J Clin Pharmacol; 2002 Jun; 58(3):177-80. PubMed ID: 12107602
[TBL] [Abstract][Full Text] [Related]
10. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
11. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive drug-associated sexual dysfunction: a prescription analysis-based study.
al Khaja KA; Sequeira RP; al Damanhori AH; Mathur VS
Pharmacoepidemiol Drug Saf; 2003; 12(3):203-12. PubMed ID: 12733473
[TBL] [Abstract][Full Text] [Related]
14. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
[TBL] [Abstract][Full Text] [Related]
15. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
[TBL] [Abstract][Full Text] [Related]
16. Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).
Tardif JC; Curnew GP; Leclerc JM; Rehel B
Can J Clin Pharmacol; 2008; 15(2):e177-87. PubMed ID: 18515919
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
19. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F
Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
[TBL] [Abstract][Full Text] [Related]
20. Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.
Chang J; Yang W; Fellers T; Kahler KH; Orloff J; Xie J; Tsaneva M; Yu AP; Wu EQ
Curr Med Res Opin; 2010 Sep; 26(9):2203-12. PubMed ID: 20673201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
